Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
227 articles on this topic
-

What Is Semax Used For? Evidence and Status
Semax is used in Russia for defined neurological and optic-nerve indications. In the United States, interest centers on focus and memory, but the human evidence for those nootropic uses is small and indirect.
-

The FDA Peptide Decision Hasn't Been Made Yet
An FDA advisory panel voted on seven peptides in July. Weeks on, nothing has been published — and that gap is the whole story.
-

FDA Peptide Warning Letters: What They Mean
FDA’s five August 24 letters targeted the way online sellers presented injectable peptides for people—not peptide molecules as a class. Here’s what changed, what didn’t, and how a prescription route differs.
-

BPC-157 Arginate vs Acetate: What Changes?
Arginate and acetate name salt forms of the same 15-amino-acid peptide. The counter-ion may change formulation properties, but no published in-vivo comparison shows that one produces better clinical outcomes.
-

Does Tesamorelin Work? What the Trials Show
Tesamorelin reduced visceral abdominal fat in two large phase 3 trials, but those studies involved adults with HIV-associated lipodystrophy. The evidence does not establish it as a general weight-loss medication or promise the same result for every patient.
-

DSIP Benefits: What the Human Evidence Shows
DSIP has been studied most directly for sleep, but the human findings are small, old and mixed. Signals involving ACTH, chronic pain and withdrawal are preliminary rather than established benefits.
-

Is Semaglutide a GLP-1? What the Class Means
Yes. Semaglutide is a GLP-1 receptor agonist and an engineered peptide. Those labels describe two different things: the receptor it activates and the structure of the medication.
-

N-Acetyl Semax Amidate: Claims vs Evidence
N-acetyl Semax amidate caps both ends of Semax, but the stability and potency claims run ahead of the evidence: no published human trial has tested this variant.
-

Semaglutide Pyridoxine: What Vitamin B6 Adds
Semaglutide/pyridoxine is a compounded combination of semaglutide and vitamin B6. Some compounders add B6 with nausea in mind, but no clinical trial has shown that the combination reduces GLP-1 nausea.
-

Sermorelin Tablets: Do Oral Forms Work?
Tablets, troches and rapid-dissolve forms sound simpler than an injection. The unresolved question is whether they deliver intact sermorelin into the bloodstream in a reliable amount.
-

Tirzepatide vs Semaglutide Side Effects
Neither medication has fewer side effects in every setting: dose, treatment population and the individual matter more than a simple ranking.
-

BPC-157 Half-Life: What the Evidence Shows
The human half-life of BPC-157 has not been established. Animal studies measured the intact peptide in minutes, not hours, while detection tests and biological effects answer different questions.
-

PT-141 Benefits: What the Human Trials Show
The strongest evidence is specific: studies found higher desire scores and less distress about low desire in premenopausal women with HSDD. Earlier, smaller trials in men measured erectile response, not broad sexual performance.
-

Semaglutide Glycine: Why Some Pharmacies Add It
Semaglutide with glycine is a compounded combination. Glycine may be described as a formulation aid or wellness additive, but no clinical trial shows that the pairing improves semaglutide outcomes.
-

Semaglutide Injections: A Practical Guide
Semaglutide is usually injected once a week, but the device, missed-dose rule, storage window and disposal steps depend on the exact product prescribed.
-

Tesamorelin vs CJC-1295: Evidence and Differences
Both peptides signal through the GHRH receptor, but their structures, duration and human evidence differ sharply. The clearest distinction is phase 3 visceral-fat data for tesamorelin versus biomarker studies for CJC-1295.
-

Thymosin Alpha-1 Benefits: What Studies Show
Thymosin alpha-1 has a credible immune-modulating mechanism, but its human evidence is condition-specific and mixed. The strongest trials do not support a blanket promise of stronger immunity.
-

BPC-157 Benefits: What the Evidence Actually Shows
BPC-157 has been studied across connective tissue, gut, inflammatory, nerve, and vascular models. The catch is decisive: most findings come from animals or cells, not controlled human trials.
-

Does Semaglutide Expire? Pens, Vials, and BUDs
Yes, semaglutide expires, but the date depends on whether it is an Ozempic pen, a Wegovy single-dose pen, or a compounded vial. The printed expiration date or beyond-use date always wins.
-

Is Tesamorelin FDA Approved? Not Every Form
Egrifta has an indication-specific approval for adults with HIV and lipodystrophy. Tesamorelin offered here is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation is not FDA-approved.
Page 7 of 12 · 227 articles